Myrexis Reorganizes to Align Resources With Current Pipeline; Reduces 41% of Workforce

Myrexis, Inc. MYRX today announced a corporate reorganization to focus resources on its current portfolio of clinical and preclinical drug candidates. The reorganization includes an immediate reduction in the Company's workforce by 57 employees or approximately 41%. The reduction was primarily in the Company's internal drug discovery group and related support functions. In addition, Myrexis will close its research services business. The Company will retain a critical translational science capability to continue to support the advancement of its two clinical and two preclinical programs.